Renal cell carcinoma left kidney icd 10

The following codes as of April 2022 are provided as a reference and may be relevant when billing for KEYTRUDA and its administration. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of its use and for information on additional codes. Diagnosis codes should be selected only by a health care professional. You are solely responsible for determining the appropriate codes and for any action you take in billing.

When submitting a claim for KEYTRUDA, always verify coding requirements with the relevant payer. Coding requirements may vary by insurer or plan; please refer to the payer-specific policies to understand what may be covered.

Check with the relevant payer regarding guidance on which diagnoses they will recognize and the applicability of secondary codes. Health care professionals are solely responsible for selecting codes that appropriately reflect the patient’s diagnosis, the services rendered, and the applicable payers’ guidelines.

Providers should document the diagnosis with a sufficiently high degree of specificity based on the information available to enable the identification of the most appropriate code. Although CMS has said that an unspecified code may be appropriate in some cases, CMS has advised that you should always code with as much specificity as possible consistent with the clinical documentation.

Merck and its agents make no warranties concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. Merck cautions that payer-coding requirements vary and can frequently change, so it is important to regularly check with each payer or, where applicable, the Medicare Administrative Contractor as to payer-specific requirements. The use of this information does not guarantee payment or that any payment received will cover your costs.

Indication

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

FDA-Approved Dosing

The FDA-approved dose of KEYTRUDA for treatment of adult patients with advanced RCC is either 200 mg administered after dilution as an intravenous infusion over 30 minutes every 3 weeks or 400 mg administered after dilution as an intravenous infusion over 30 minutes every 6 weeks, in combination with axitinib 5 mg orally twice daily until disease progression, unacceptable toxicity, or for KEYTRUDA, up to 24 months. When axitinib is used in combination with KEYTRUDA, dose escalation of axitinib above the initial 5 mg dose may be considered at intervals of 6 weeks or longer.

See also the Prescribing Information for recommended axitinib dosing information.

The recommended dose of KEYTRUDA for the adjuvant treatment of adult patients with RCC is 200 mg administered after dilution as an intravenous infusion over 30 minutes every 3 weeks or 400 mg administered after dilution as an intravenous infusion over 30 minutes every 6 weeks until disease recurrence, unacceptable toxicity, or up to 12 months.

KEYTRUDA is indicated for use at an additional recommended dosage of 400 mg every 6 weeks for all approved adult indications. This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.

See full Prescribing Information for preparation and administration instructions and dosage modifications for adverse reactions.

Advanced search lets you search selected properties of the classification. You could search all properties or a selected subset only

First, you need to provide keywords in the Search Text field then check the properties that you'd like to include in the search.

The system will search for the keywords in the properties that you've checked and rank the results similar to a search engine

The results will be displayed in the Search Results pane. If the search query hits more than 200 results, then only the top 200 will be displayed.

If you provide more than one keyword, the system will search for items that have all the keywords.

Wildcards: You may also use wildcard character * . see examples below.

OR operator : It's possible to have the results that have either one or another keyword. Please see the example 4.

Examples:

1. Search Text: diabetes   {finds all that have the word "diabetes" in the searched fields}

2. Search Text: diabet*   {finds all that have a word that start with "diabet" }

3. Search Text: diabet* mellitus   {finds all that have a word that starts with "diabet" and also contains the word "mellitus"}

4. Search Text: tubercul* (lung OR larynx) { finds all that have a word that starts with "tubercul" and than has either lung OR larynx in it

Search Results

After the search the results are displayed at the lower right area of the screen. Here the porgram lists the titles of the ICD categories in which your search keywords are found.

What is the ICD

What is the ICD

Is renal cancer the same as renal cell carcinoma?

What is another name for renal cell carcinoma?